InspireMD Gestion

Gestion contrôle des critères 1/4

Le PDG InspireMD est Marvin Slosman, nommé en Jan2020, a un mandat de 4.83 ans. La rémunération annuelle totale est $ 3.22M, composée du salaire de 14.6% et des bonus 85.4%, y compris les actions et options de la société. détient directement 0.025% des actions de la société, d'une valeur de € 16.14K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.2 ans et 8.2 ans.

Informations clés

Marvin Slosman

Directeur général

US$3.2m

Rémunération totale

Pourcentage du salaire du PDG	14.6%
Durée du mandat du directeur général	4.8yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	1.2yrs
Durée moyenne du mandat des membres du conseil d'administration	8.2yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Marvin Slosman a-t-elle évolué par rapport aux bénéfices de InspireMD?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$3m	US$470k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$697k	US$433k	-US$18m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$410k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$367k	-US$11m

Rémunération vs marché: La rémunération totale de Marvin ($USD 3.22M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 472.15K ).

Rémunération et revenus: La rémunération de Marvin a augmenté alors que l'entreprise n'est pas rentable.

PDG

Marvin Slosman (60 yo)

4.8yrs

Titularisation

US$3,219,321

Compensation

Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% € 16.1k
Craig Shore	CFO, Chief Administrative Officer	1.1yrs	US$1.80m	9.2% € 6.1m
Shane Gleason	Chief Commercial Officer	1.3yrs	US$1.15m	2.08% € 1.4m
Andrea Tommasoli	Chief Operating Officer	1.7yrs	US$359.27k	1.94% € 1.3m
Amir Kohen	Senior Vice President of Finance & HR	1.1yrs	pas de données	pas de données
Patrick Verta	Executive Vice President of Clinical & Medical Affairs	1.1yrs	pas de données	0.71% € 470.5k
Pete Ligotti	Executive VP & GM of North America	less than a year	pas de données	pas de données
Sol Barer	Special Advisor to the Board	no data	US$13.92k	pas de données

1.2yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de II2 n'est pas considérée comme expérimentée (ancienneté moyenne 1.2 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% € 16.1k
Michael Berman	Independent Director	11.8yrs	US$380.25k	1.59% € 1.0m
Elazer Edelman	Member of Advisory Board	no data	pas de données	pas de données
Thomas Kester	Independent Director	8.2yrs	US$385.25k	1.25% € 824.8k
Antonio Colombo	Member of Advisory Board	no data	pas de données	pas de données
Alexandre Abizaid	Member of Advisory Board	no data	pas de données	pas de données
Martin B. Leon	Member of Advisory Board	no data	pas de données	pas de données
Eberhart Grube	Member of Advisory Board	no data	pas de données	pas de données
Paul Stuka	Independent Chairman of the Board	13.3yrs	US$574.93k	1.19% € 786.6k
Kenneth Rosenfield	Chair of Scientific Advisory Board	3.6yrs	pas de données	pas de données
Yaron Almagor	Member of Advisory Board	no data	pas de données	pas de données
Edo Kaluski	Member of Advisory Board	no data	pas de données	pas de données

8.2yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de II2 sont considérés comme expérimentés (ancienneté moyenne 8.2 ans).

InspireMD Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Insider recently bought €116k worth of stock

InspireMD, Inc. Announces Management Appointments

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

Recent updates

InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024

InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$0.82 loss per share (vs US$2.35 loss in FY 2022)

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Insider recently bought €116k worth of stock

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.59 loss in 2Q 2022)

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.53 loss in 3Q 2021)

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought €67k worth of stock

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.46 loss in 2Q 2021)

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

Insider recently bought €88k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

Insider recently bought €79k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Revenue misses expectations

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: €0.88

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: €0.64

New 90-day high: €0.50

Revenue beats expectations

Third quarter 2020 earnings released: US$0.064 loss per share

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing

InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

InspireMD, Inc. announced that it has received $0.1 million in funding

InspireMD Announces Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives

InspireMD, Inc. to Report Q3, 2019 Results on Nov 12, 2019

New 90-day low: €0.28

InspireMD, Inc.(AMEX:NSPR) dropped from S&P TMI Index

New 90-day low - €0.32

New 90-day low - €0.35

InspireMD Regains Compliance with NYSE Listing Standards

InspireMD, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Analyse de la rémunération des PDG

PDG

Titularisation